Search
for
Sort by
Research 30 of 280
- Postmarketing Surveillance of New Antiepileptic Drugs: The Tribulations of Trials
- Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
- Changes in European Legislation Make it Timely to Introduce a Transparent Market Surveillance System for Cosmetics
- Failing Public Health Again? Analytical Review of Depression and Suicidality From Finasteride
- Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors
- Ethinylestradiol/Chlormadinone Acetate
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants
- Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems
- Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
- Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Specialization and the Physician Workforce
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- ‘Post-finasteride syndrome’: what to tell our female patients?
- Topical imiquimod—Be aware of the unexpected
- A case of widespread actinic granuloma with associated drug-induced lupus erythematosus
- Urticariform plaques: delayed hypersensitivity reaction type IV to enoxaparin
- Side Effects of 5‐Alpha Reductase Inhibitors: A Comprehensive Review
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
- Evidence or Experience: That is the Question
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- Association of Suicidality and Depression With 5α-Reductase Inhibitors
- Severe hair loss associated with psyc hotropic drugs in psychiatric inpatients—Data from an observational pharmacovigilance program in German-speaking countries
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Menopause and Common Dermatoses: A Systematic Review